ORGANIZATION

• Role of IP Division Shifting to Partner Hunt and Dealmaking: JPMA Official
  February 5, 2025

• Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
  January 29, 2025

• JPMA Exec Urges Rethink of Social Security Funding; Comments on Trump’s Policy
  January 24, 2025

• Japan Biosimilar Association Ready to Play Its Roles under Govt Roadmap
  January 17, 2025

• JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
  January 14, 2025

• Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
  January 9, 2025

• Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope
  January 9, 2025

• FPMAJ Chair Calls for Sufficient Consensus on Drug Discovery Support Fund
  January 7, 2025

• 4-Ministers’ Pact Has Effectively Been Scrapped with 2025 Off-Year Revision Plan: FPMAJ Chair
  January 7, 2025

• As 2025 Begins, Industry Leaders Renew Resolve towards Next Reforms
  January 6, 2025

• Japan Generic Use Rate at 84.7% in July-September: JGA
  December 27, 2024

• PhRMA/EFPIA Lash Out at Japan’s Plan for Mandatory Startup Fund
  December 26, 2024

• PhRMA/EFPIA Slam Govt for Off-Year Revision as Broader Industry Deplores Decision
  December 26, 2024

• Off-Year Revisions Need Careful Assessments and Discussions: Chuikyo JMA Rep
  December 20, 2024

• JPMA to Continue Seeking Repeal of Off-Year Revisions: Exec
  December 20, 2024

• JPA Calls for Improving Package Units as Pharmacies Suffer with Unsold Stocks of Pricey Meds
  December 19, 2024

• Japan Citizens’ Group Opposes RWD-Only Drug Submissions
  December 16, 2024

• EFPIA Japan Issues Joint Statement for Resolving Drug Lags/Losses
  December 12, 2024

• Pharma Labor Group Petitions MHLW to Scrap Off-Year Revisions
  December 3, 2024

• DPP Head, Industry Leaders United towards Stopping Off-Year Price Revisions
  November 29, 2024

ページ

• « 先頭
• ‹ Prev
• …
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• …
• Next ›
• 最終 »